Nuvectis reports Q2 2026 results as ciprocopan wins first China approval

Nuvectis Pharma reported second quarter 2026 results on August 4, 2026, highlighting the approval of its lead candidate ciprocopan (NXP100) in China. The company's lead drug candidate, ciprocopan (NXP100), a Complement Factor B inhibitor for once-daily, oral administration, was approved in China in July 2026 for the treatment of patients with PNH previously untreated with complement inhibitors.¹ The approval came through Nuvectis's partner Haisco Pharmaceutical Group. A separate marketing application in China for treating PNH patients previously treated with anti-C5 therapy is under review.¹

On the U.S. regulatory front, a pre-IND meeting with the FDA followed by IND submission for ciprocopan is expected in the fourth quarter of 2026.¹ For NXP200, the company's brain-penetrant BRAF inhibitor, a Phase 1b study in China in patients with BRAF-mutated solid tumors is ongoing,¹ with a U.S. IND submission also expected in the fourth quarter of 2026.¹ Additional Haisco-generated clinical data on NXP200 will be presented at ESMO in Madrid from October 23 to 27, 2026, according to the release.

For NXP900, the SRC family kinase inhibitor, Nuvectis said the combination trial with osimertinib in NSCLC EGFR+ patients who progressed on osimertinib is ongoing, with an update expected by year end,¹ while a combination study with lorlatinib in NSCLC ALK+ patients is expected to begin in the third quarter of 2026.¹ An investigator-sponsored trial combining NXP900 with daraxonrasib in pancreatic cancer is planned, contingent on FDA approval and availability of daraxonrasib.¹

On financials, cash and cash equivalents were $22.2 million as of June 30, 2026, compared to $31.6 million as of December 31, 2025.¹ The company completed a follow-on offering in July 2026, raising $115 million in gross proceeds, anchored by leading healthcare dedicated investors and extending the cash runway into the first half of 2029.¹